AstraZeneca retires Medimmune name amid sales turnaround
WEBFeb 14, 2019 · After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing restructuring efforts.
AstraZeneca forges $500M cancer immunotherapy buyout for MedImmune
WEBAug 26, 2013 · AstraZeneca is rolling the dice on a $500 million deal--including $225 million upfront--to buy the early-stage cancer immunology specialist Amplimmune for its U.S. biologics arm MedImmune.
MedImmune Receives FDA Approval for Self-Administered Flu …
WEB1 day ago · Sep 20, 2024 9:58am. By Connor Hart. AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a ...
MedImmune completes $500m acquisition of Amplimmune
WEBOct 8, 2013 · AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics...
Press Release: AstraZeneca to acquire MedImmune
WEBApr 23, 2007 · MedImmune adds an exciting existing pipeline, including 2 late-stage products, great expertise in biologic drug development and state of the art manufacturing facilities.
AstraZeneca spins out new biotech, shedding autoimmune drugs
WEBFeb 28, 2018 · MedImmune, AstraZeneca plc’s biologics R&D unit, will spin out six experimental drugs into a standalone biotech, aiming to speed development of assets that fall outside of its core areas of research.
AstraZeneca near deal to buy MedImmune - WSJ | Reuters
WEBBritain's AstraZeneca Plc <AZN.L> is near a deal to buy U.S. biotechnology company MedImmune Inc. <MEDI.O> in a transaction that could be worth more than $13 billion, the Wall Street Journal...
Medimmune'in(Licenses'cancer'immunotherapy'tremelimumab'from ... - Pfizer
WEBOct 3, 2011 · MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody.
AstraZeneca oncology portfolio strengthened as MedImmune
WEBOct 15, 2013 · AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate...
FDA approves at-home FluMist administration | CIDRAP
WEB1 day ago · The Food and Drug Administration (FDA) today announced that it has approved self- or caregiver-administered FluMist, making it the first flu vaccine that doesn’t have to be administered by a healthcare provider. In a statement, the FDA said that MedImmune, the maker of FluMist, plans to offer the vaccine through a third-party pharmacy.